Skip to content

Interpres Security

Threat exposure management platform mapping defensive controls against real adversary capabilities to prioritize what actually reduces risk.

Visit Website ↗ + Add to Compare
55/100Incremental Innovator

Overview

Interpres Security built a platform for continuous threat exposure management (CTEM), analyzing the relationship between an organization’s actual defensive controls and known adversary tactics to prioritize remediation based on what genuinely reduces exploitable risk, rather than generic vulnerability counts. This control-validation angle differentiates it from pure vulnerability scanners.

Founded in 2020 and based in Mount Pleasant, South Carolina, Interpres raised $8.5 million in a 2022 seed round before being acquired by CyberProof in December 2024. The acquisition folds its technology into a larger managed security services provider’s offering, which validates the approach commercially but means Interpres no longer operates as an independent innovator.

Innovation Matrix Assessment

Innovation Velocity 6/10

Built a differentiated control-validation approach to exposure management within a few years of founding.

Operational Value 6/10

Helps security teams prioritize fixes based on actual adversary-vs-defense mapping rather than raw vulnerability volume.

Market Momentum 5/10

A modest $8.5M seed round followed by acquisition suggests real but limited independent commercial traction before being absorbed.

Category Disruption 5/10

Adds a genuinely useful control-validation lens to exposure management, within an increasingly crowded CTEM category.

Real-World Efficacy 5/10

Limited independent, post-acquisition evidence of efficacy is publicly available.

Enduring Relevance 6/10

Continuous threat exposure management remains a growing priority as attack surfaces expand.

Why CISOs Should Care

Helps prioritize security investment based on validated coverage against real adversary techniques, not just raw CVE counts.

What Makes It Different

Maps defensive control efficacy directly against adversary capability data, rather than scoring exposure by vulnerability severity alone.

The Matrix Verdict

55/100 — INCREMENTAL INNOVATOR

A promising exposure-management approach validated by acquisition; now operates as part of CyberProof rather than independently.

Editorial Note: Claims vs. Verified Findings

Now part of CyberProof following the December 2024 acquisition; independent product roadmap status is unclear.

Sources